CDKN2B

Across TCGA pan-cancer cohorts, CDKN2B mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of CDKN2B’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where CDKN2B mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types CDKN2B is over-expressed in tumor, although a few such as LUAD and HNSC show the opposite, repressed pattern.

PDAC, LUAD, and HNSC are the cancer types where CDKN2B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CDKN2B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	All	All	+0.836	<.001	6	view →
LUAD	All	All	−0.348	<.001	6	view →
HNSC	Male	All	−0.590	.002	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

CDKN2B–PDAC

Open the PDAC breakdown →